Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D W Harron

Showing results (11-20 of 87) with videos related to

Pageof 9
Sort By:
Drugs|December 1, 1987
Propafenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmiasD W Harron, R N Brogden
European Heart Journal|September 1, 1985
Pharmacology, clinical pharmacology and potential therapeutic uses of the specific bradycardiac agent alinidineD W Harron, R G Shanks
British Journal of Pharmacology|January 1, 1989
Atenolol, but not mexiletine, protects against stimulus-induced ventricular tachycardia in a chronic canine modelA C Uprichard, D W Harron
Arzneimittel-Forschung|January 1, 1985
Investigations into the bradycardic action of indoraminC Lillie, D W Harron, W Kobinger
European Journal of Pharmacology|September 3, 1984
Effects of peripheral alpha 1- and alpha 2-adrenoceptor agonists on baroreceptor responsiveness in conscious dogsD W Harron, W Kobinger, C Lillie
European Journal of Pharmacology|June 8, 1990
Acute and chronic effects of rilmenidine on baroreflex function in conscious dogsJ P Spiers, D W Harron, R Wilson
Journal of the Royal College of Physicians of London|April 1, 1983
Slow release beta-adrenoceptor blocking drugsD W Harron, A Howe, R G Shanks
British Medical Journal (Clinical Research Ed.)|June 13, 1981
Debendox and congenital malformations in Northern IrelandR G Shanks, K Griffiths, D W Harron
British Medical Journal|November 22, 1980
Debendox and congenital malformations in Northern IrelandD W Harron, K Griffiths, R G Shanks
The Journal of Pharmacy and Pharmacology|January 1, 1991
Duration of action and effect on baroreflex function of the anti-arrhythmic alpha 1 antagonist UK-52,046J P Spiers, D W Harron, R Wilson
Pageof 9

Showing results (11-20 of 87) with videos related to

Sort By:
Pageof 9
Drugs|December 1, 1987
Propafenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmiasD W Harron, R N Brogden
European Heart Journal|September 1, 1985
Pharmacology, clinical pharmacology and potential therapeutic uses of the specific bradycardiac agent alinidineD W Harron, R G Shanks
British Journal of Pharmacology|January 1, 1989
Atenolol, but not mexiletine, protects against stimulus-induced ventricular tachycardia in a chronic canine modelA C Uprichard, D W Harron
Arzneimittel-Forschung|January 1, 1985
Investigations into the bradycardic action of indoraminC Lillie, D W Harron, W Kobinger
European Journal of Pharmacology|September 3, 1984
Effects of peripheral alpha 1- and alpha 2-adrenoceptor agonists on baroreceptor responsiveness in conscious dogsD W Harron, W Kobinger, C Lillie
European Journal of Pharmacology|June 8, 1990
Acute and chronic effects of rilmenidine on baroreflex function in conscious dogsJ P Spiers, D W Harron, R Wilson
Journal of the Royal College of Physicians of London|April 1, 1983
Slow release beta-adrenoceptor blocking drugsD W Harron, A Howe, R G Shanks
British Medical Journal (Clinical Research Ed.)|June 13, 1981
Debendox and congenital malformations in Northern IrelandR G Shanks, K Griffiths, D W Harron
British Medical Journal|November 22, 1980
Debendox and congenital malformations in Northern IrelandD W Harron, K Griffiths, R G Shanks
The Journal of Pharmacy and Pharmacology|January 1, 1991
Duration of action and effect on baroreflex function of the anti-arrhythmic alpha 1 antagonist UK-52,046J P Spiers, D W Harron, R Wilson
Pageof 9